Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Implementing Improved Blood Pressure Measurement in General Practice: A Multisite Implementation Trial Using Automated Office Blood Pressure (AOBP)

keskiviikko 9. syyskuuta 2026 päivittänyt: James E Sharman, Menzies Institute for Medical Research

The goal of this clinical trial is to evaluate whether implementation of guideline-recommended Automated Office Blood Pressure (AOBP) measurement in Australian general practice clinics improves hypertension control among adults aged 18 years and older who are eligible for blood pressure assessment as part of routine clinical care. The study will also evaluate the implementation, sustainability, and health economic impact of AOBP in real-world primary care settings.

The main questions it aims to answer are:

  • Does implementation of AOBP increase the proportion of patients with treated and controlled hypertension compared with the pre-implementation period?
  • Can AOBP be successfully adopted, implemented, integrated into routine general practice workflows, and maintained over time?

Researchers will compare outcomes following implementation of AOBP with routinely collected clinical data from the period before implementation.

Participants will:

  • Provide informed consent and have their AOBP measurements performed during routine general practice visits.
  • Consent to the collection of AOBP measurement and relevant clinical information from their medical records for study evaluation.
  • Continue to receive usual clinical care from their general practitioner.

General practice staff will receive AOBP training, perform AOBP measurements, and participate in implementation evaluation activities.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Hypertension is the most common condition managed in general practice and remains one of the leading modifiable risk factors for cardiovascular disease (CVD). Accurate blood pressure (BP) measurement is fundamental to hypertension diagnosis and management; however, guideline-recommended clinic BP measurement procedures are often difficult to implement in routine practice because of time, staffing, and workflow constraints. General practitioners have reported that guideline-recommended BP measurement approaches are frequently impractical in routine clinical care, which may contribute to reduced confidence in clinic BP readings and therapeutic inertia.

Automated Office Blood Pressure (AOBP) measurement is a standardized approach to clinic BP assessment designed to reduce observer and procedural bias. The method incorporates an automated rest period followed by repeated automated measurements obtained while the patient remains seated, quiet, and undisturbed. AOBP values correlate closely with out-of-office BP measurement methods and, in 2025, AOBP was endorsed by Hypertension Australia and the National Hypertension Taskforce as the recommended standard for clinic BP measurement in Australia.

AOBP is typically performed by a trained staff member before the patient sees the general practitioner, in a quiet area outside the consultation room. This approach is intended to provide a more standardized BP assessment, reduce demands on consultation time, and support clinical decision-making through more reliable BP information while maintaining existing clinical care pathways and clinician responsibility for diagnosis, treatment, follow-up, and referral decisions.

Despite guideline endorsement and supporting evidence, AOBP has not been routinely implemented in Australian general practice. Barriers to implementation are predominantly structural rather than clinical and include limited access to validated equipment, staff training requirements, workflow integration challenges, and the absence of coordinated implementation support.

The study was informed by extensive co-design work involving general practitioners, practice staff, partner organisations, and community members. Previous pilot implementation work demonstrated that AOBP could be integrated into general practice workflows and was considered feasible, acceptable, and adaptable across diverse practice settings when supported by appropriate training, workflow integration, and governance arrangements. GPs participating in pilot implementation work reported increased trust in BP readings and greater confidence in hypertension management.

This study is a pragmatic, multisite, hybrid type 2 implementation-effectiveness trial using a non-randomised pre-post design. Approximately 40 Australian general practice clinics will participate in the study, with implementation occurring within each clinic over a 12-month period followed by a 6-month maintenance phase. The study has been designed to evaluate implementation of Automated Office Blood Pressure (AOBP) measurement within routine primary care settings and examine factors influencing implementation and sustainability in general practice.

The hybrid type 2 implementation-effectiveness design was selected to enable simultaneous evaluation of implementation and effectiveness under real-world conditions. Evaluation is guided by the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework and the Practical, Robust Implementation and Sustainability Model (PRISM). RE-AIM provides the overarching framework for evaluation of effectiveness and implementation outcomes, while PRISM is used to identify barriers, enablers, contextual factors, adaptations, and determinants of implementation and sustainability.

In addition to implementation and effectiveness evaluations, the study will examine health economic considerations associated with implementation of AOBP in general practice and will explore longer-term health outcomes through approved linkage to routinely collected administrative and health datasets where available. These evaluations are intended to complement trial findings and inform future implementation, scale-up, and sustainability of AOBP in Australian primary care settings.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

6000

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Tasmania
      • Hobart, Tasmania, Australia, 7000
        • Menzies Institute for Medical Research, University of Tasmania
        • Ottaa yhteyttä:
        • Päätutkija:
          • James E Sharman, PhD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Inclusion Criteria:

Patients will be eligible to participate if they meet Australian guideline-recommended criteria for BP measurement, either for absolute CVD risk assessment or for BP assessment as an individual risk factor, and are attending a participating general practice clinic during the study period.

Eligible participants include:

Adults attending participating general practice clinics who are eligible for BP measurement for absolute CVD risk assessment, including:

  • Adults aged 45 to 79 years without known CVD
  • Adults aged 35 to 79 years with diabetes and without known CVD
  • First Nations peoples aged 30 to 79 years without known CVD

Adults eligible for BP assessment as an individual risk factor, including:

  • First Nations peoples aged 18 to 29 years
  • Adults aged 18 years and over where BP measurement is clinically indicated based on individual risk factors or clinical judgement (e.g. suspected hypertension from BP measurements outside the clinic, obesity, abnormal cholesterol levels, secondary causes of hypertension, or time elapsed since last BP measurement)

Exclusion Criteria:

  • Patients who are unable to provide informed consent.
  • Patients whose participation is deemed clinically inappropriate by the treating general practitioner.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Terveyspalvelututkimus
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Muut: AOBP Implementation Intervention
Implementation of a standardized AOBP measurement protocol using a validated automated sphygmomanometer. AOBP measurements will be conducted by trained general practice staff. Patients will be seated in a quiet area with back supported, feet flat on the floor, arm supported at heart level, and an appropriately sized cuff applied. Following a 5-minute automated rest period, the device automatically records three seated blood pressure measurements at 30-second intervals and a fourth brief measurement to detect arrhythmia/atrial fibrillation. The device automatically calculates and records the average of the three seated measurements, heart rate, and arrhythmia status. Where clinically indicated, a standing protocol will be performed following the seated protocol and consists of two standing blood pressure measurements recorded at 30-second intervals after 1 minute of standing, followed by an arrhythmia assessment. Results are provided to the treating general practitioner.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
The proportion of patients with treated and controlled hypertension, with the primary estimand being the absolute difference in this proportion between the pre-implementation period and 12-month AOBP implementation period.
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.

Hypertension control will be defined according to Australian guideline recommendations using AOBP thresholds (average systolic BP <135 mmHg and diastolic BP <85 mmHg).

"Treated" refers to patients receiving antihypertensive therapy.

Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Average systolic and diastolic BP measured using AOBP
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Heart rate recording during AOBP measurement
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Frequency of repeat AOBP measures during the study period
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Changes in systolic and diastolic blood pressure values over time, measured using AOBP
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Clinician-measured BP values recorded in the electronic medical record, where available
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Initiation of antihypertensive therapy
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Intensification of antihypertensive therapy
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Changes in antihypertensive medication prescribing patterns
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Changes in cardiovascular medication prescribing patterns
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Proportion of participants receiving treatment for hypertension
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Documented referral for further assessment related to elevated BP (detected by AOBP device)
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Documented follow-up investigations related to elevated BP (detected by AOBP device [e.g. electrocardiogram monitoring, standard clinic blood pressure measurement, home BP monitoring, 24-hour ambulatory BP monitoring])
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Dates of clinic visits related to elevated BP (detected by AOBP device), where available
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Proportion of participants with possible arrhythmia (including AF) indicated by the AOBP device
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Documented referral for further assessment of possible arrhythmia (including AF) indicated by the AOBP device
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Dates of clinic visits related to possible arrhythmia (including AF) indicated by AOBP device, where available
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Completion of an absolute CVD risk calculation
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Documentation of patient characteristics relevant to cardiovascular risk (e.g. age, sex, smoking status, relevant CVD risk factors and pathology [i.e. cholesterol, glucose] and clinical conditions such as diabetes)
Aikaikkuna: Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Assessed during the 12-month AOBP implementation period. Patients included in longitudinal treatment-response analyses must have ≥6 weeks of follow-up after the index AOBP measurement.
Implementation outcomes will be evaluated within the overarching RE-AIM framework and will include measures of Reach, Adoption, Implementation and Maintenance.
Aikaikkuna: Assessed throughout the 12-month AOBP implementation period, with Maintenance assessed at 18 months following the 6-month maintenance phase.
These will examine participation and uptake of AOBP, fidelity, feasibility, acceptability, integration into routine practice, and sustained use during the maintenance period.
Assessed throughout the 12-month AOBP implementation period, with Maintenance assessed at 18 months following the 6-month maintenance phase.
PRISM (Practical, Robust Implementation and Sustainability Model) will guide the implementation component by identifying anticipated and experienced barriers and enablers, and contextual factors influencing implementation and sustainability.
Aikaikkuna: Assessed throughout the 12-month AOBP implementation period, with Maintenance assessed at 18 months following the 6-month maintenance phase.
Assessed throughout the 12-month AOBP implementation period, with Maintenance assessed at 18 months following the 6-month maintenance phase.
Costs associated with implementation of AOBP at the practice level, including equipment, staff training, workflow integration, and ongoing quality assurance
Aikaikkuna: Outcome assessed 12-months following AOBP implementation period.
Outcome assessed 12-months following AOBP implementation period.
Costs per patient correctly diagnosed and managed for hypertension using AOBP compared with usual care BP measurement
Aikaikkuna: Outcome assessed 12-months following AOBP implementation period.
Outcome assessed 12-months following AOBP implementation period.
Practice level and system level costs related to changes in clinical management, including antihypertensive prescribing and follow up
Aikaikkuna: Outcome assessed 12-months following AOBP implementation period.
Outcome assessed 12-months following AOBP implementation period.
Downstream health service utilisation and cost implications associated with CVD events, hospitalisations, and mortality (where data permit)
Aikaikkuna: Outcome assessed 12-months following AOBP implementation period.
Outcome assessed 12-months following AOBP implementation period.

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Cardiovascular disease risk factors ascertained via data linkage
Aikaikkuna: Exploratory outcome assessed 12-months following AOBP implementation period.
Obesity, hypertension, hyperlipidaemia, Type II diabetes mellitus, smoking status
Exploratory outcome assessed 12-months following AOBP implementation period.
Death
Aikaikkuna: Exploratory outcome assessed 12-months following AOBP implementation period.
CVD death, all-cause mortality
Exploratory outcome assessed 12-months following AOBP implementation period.
Hospitalization ascertained via data linkage
Aikaikkuna: Exploratory outcome assessed 12-months following AOBP implementation period.
Emergency department presentations, public hospital admissions, private hospital admissions
Exploratory outcome assessed 12-months following AOBP implementation period.
Cardiovascular disease events ascertained via data linkage
Aikaikkuna: Exploratory outcome assessed 12-months following AOBP implementation period.
Including: angina, acute myocardial infarction, ischemic heart disease, cardiomyopathy, atrial fibrillation, hypertensive heart disease, heart failure, heart valve disease, presence of cardiac and vascular implants and grafts, cerebrovascular disease, peripheral artery disease, chronic kidney disease
Exploratory outcome assessed 12-months following AOBP implementation period.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Torstai 1. lokakuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. lokakuuta 2029

Opintojen valmistuminen (Arvioitu)

Tiistai 1. lokakuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 9. syyskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 9. syyskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 16. syyskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 16. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 9. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • H40663
  • Grant ID 2053493 (Muu apuraha/rahoitusnumero: National Health and Medical Research Council of Australia)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa